All In Biotech

Drug Trial Radar · NCT06910839

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

21

Actual

Start

Mar 13, 2025

Primary completion

May 1, 2025

Study completion May 20, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

Conditions

  • Overweight
  • Obesity

Interventions

  • PF-07976016Drug

    PF-07976016 oral tablets

  • PF-06882961Drug

    PF-06882961 oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Steady state area under the concentration-time profile for PF-07976016Time frame: From 0 Hours to 24 Hours following steady-state dose
  2. Steady state maximum observed concentration (Cmax) for PF-07976016Time frame: From 0 Hours to 24 Hours following steady-state dose
  3. Steady state area under the concentration-time profile danuglipronTime frame: From 0 Hours to 24 Hours following steady-state dose
  4. Steady state maximum observed concentration (Cmax) for danuglipronTime frame: From 0 Hours to 24 Hours following steady-state dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials, LLC

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.